Reinventing BioInvent

Revival financing could help BioInvent reach data milestones in cancer

A proposed financing by BioInvent International AB (SSE:BINV) would give the cancer antibody company new life to reach clinical proof of concept for three assets and fund preclinical immuno-oncology programs that it had been forced to deprioritize.

On Feb. 16, BioInvent

Read the full 427 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers